Table 1.

Characteristics of the included studies

Author	Year	Region	Risk factor	Nystatin group			Control group			Nystatin group				Control group
				Age (mean)	Sex ratio (F:M)	N	Age (mean)	Sex ratio (F:M)	N	Formulation	Dose	Frequency (times/day)	Duration (days)	Medication	Formulation	Duration
Mima et al26	2012	Brazil	Denture	62.45 y	3:1	20	61.25 y	13:7	20	Suspension	100,000 IU	4	15	Photodynamic therapy	–	15 d
Johnson et al27	1989	USA	Denture	–	–	8 8	–	–	8	Pastille	200,000 IU 400,000 IU	5	14	Placebo	Pastille	14 d
Nairn28	1975	England	Denture	–	–	13	–	–	18 15	Pastille	500,000 IU	4	30	Amphotericin B placebo	Tablet	1 month
Goins et al29	2002	USA	Infants	1–12 mo	–	28	1–12 mo	–	17	Suspension	100,000 IU	4	10	Fluconazole	Suspension	7 d
Hoppe20	1997	Germany	Infants	130.8 d	57.6:42.4	107	132.0 d	48:52	105	Suspension	100,000 IU	4	12	Miconazole	Gel	12 d
Flynn et al30	1995	USA	Infants Children	6 mo to 13 y	–	88	6 mo to 13 y	–	94	Suspension	400,000 IU	4	14	Fluconazole	Suspension	14 d
Moshi et al31	1998	Tanzania	AIDS	15–59 y	–	91	15–59 y	–	91	Suspension	100,000 IU	3	14	Sodium benzoate	Solution	14 d
Pons et al32	1997	USA	HIV AIDS	38 y	1:7	84	38 y	1:7	83	Suspension	500,000 IU	4	14	Fluconazole	Suspension	14 d
Nyst et al33	1992	Zairian	AIDS	35.4 y	25:22	47	34.5 y	27:22 23:22	49 45	Suspension	200,000 IU	4	14	Gentian violet ketoconazole	Suspension troche	14 d
Meunier et al34	1990	Belgium	Cancer patients	–	–	24	–	–	18	Suspension + pastille	1,000,000 IU 100,000 IU	3	10–12	Ketoconazole	Tablet	10–12 d
Blomgren et al35	1998	Sweden	Multigroup patients	60.7 y	16:14	33	58.4 y	18:12	34	Solution	100,000 IU	4	21	Fluconazole	Capsule	7 d

Abbreviations: d, days; mo, months; y, years; F, female, M, male.